Deep search
Profile Picture
  • All
  • Search
  • Images
  • Videos
  • Maps
  • News
  • Copilot
  • More
    • Shopping
    • Flights
    • Travel
  • Notebook
  • Top stories
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Business
  • More
    Politics
Order byBest matchMost fresh
  • Any time
    • Past hour
    • Past 24 hours
    • Past 7 days
    • Past 30 days
The Lancet
4mon

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial

Copyright: © 2025 The Author(s). Published by Elsevier Ltd.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Trending now

SCOTUS rejects appeal
Acquires The Free Press
France’s new PM resigns
Asks Trump to end tariffs
Hikers trapped on Everest
First EF5 tornado in years
Combs asked for a pardon
Rejects Missouri's bid
Honored with Barbie doll
Judge on deployment to OR
Israel deports Thunberg
Beloved British author dies
Launches comeback bid
Running for US Senate in TX
To star in NBC opening show
Named CEO of IRS
Groups sue EPA
Faces confidence votes
CDC updates vaccine guidance
Eswatini accepts deportees
Rush to bring reunion tour
Staffing issues at airports
To buy Comerica
Boat capsizes on Danube
ISR-Hamas ceasefire talks
Asahi restarts production
To hear therapy ban case
OpenAI launches new feature
Senate rejects funding bills
Verizon names new CEO
Faces felony battery charge
Illinois sues Trump admin
Authorities probe blaze
To invest over $1B in India
Feedback
  • Privacy
  • Terms